Allosteric modulation of G protein-coupled receptor signaling

Front Endocrinol (Lausanne). 2023 Feb 16:14:1137604. doi: 10.3389/fendo.2023.1137604. eCollection 2023.

Abstract

G protein-coupled receptors (GPCRs), the largest family of transmembrane proteins, regulate a wide array of physiological processes in response to extracellular signals. Although these receptors have proven to be the most successful class of drug targets, their complicated signal transduction pathways (including different effector G proteins and β-arrestins) and mediation by orthosteric ligands often cause difficulties for drug development, such as on- or off-target effects. Interestingly, identification of ligands that engage allosteric binding sites, which are different from classic orthosteric sites, can promote pathway-specific effects in cooperation with orthosteric ligands. Such pharmacological properties of allosteric modulators offer new strategies to design safer GPCR-targeted therapeutics for various diseases. Here, we explore recent structural studies of GPCRs bound to allosteric modulators. Our inspection of all GPCR families reveals recognition mechanisms of allosteric regulation. More importantly, this review highlights the diversity of allosteric sites and presents how allosteric modulators control specific GPCR pathways to provide opportunities for the development of new valuable agents.

Keywords: G protein-coupled receptors (GPCRs); GPCR signaling regulation; allosteric drug discovery; allosteric modulator; structural investigations.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation
  • Binding Sites
  • Drug Delivery Systems*
  • Drug Development*
  • Ligands

Substances

  • Ligands

Grants and funding

This work was supported by the National Natural Science Foundation of China (32100988 to WY), Science and Technology Department of Sichuan Province (2021ZYD0080 to WY).